Average buy price is hidden here because at least one covered purchase quarter has no usable local mean price.
| Quarter | Action | Shares change | Est. value change | Δ Own | Shares held | Filing date |
|---|---|---|---|---|---|---|
| Q1 2026 | Added | +119K | – | +51.3% | 352K | May 5, 2026 |
| Q4 2025 | New | +232K | – | – | 232K | Feb 9, 2026 |
| Q4 2021 | Added | +194K | – | +34.1% | 764K | Feb 2, 2022 |
| Q3 2021 | New | +569K | – | – | 569K | Oct 26, 2021 |
Yes. As of Q1 2026, Ken Fisher disclosed 352K shares of BBIO, worth an amount we cannot price. All figures come from SEC 13F filings for Q1 2026, the latest disclosed quarter.
Ken Fisher first disclosed a BBIO position in Q3 2021; every quarterly buy and sell since is in the table above. All figures come from SEC 13F filings for Q1 2026, the latest disclosed quarter.
The quarter-by-quarter table above shows each sale and reduction Ken Fisher disclosed in BBIO. All figures come from SEC 13F filings for Q1 2026, the latest disclosed quarter.
Ken Fisher disclosed 352K shares of BBIO as of Q1 2026. All figures come from SEC 13F filings for Q1 2026, the latest disclosed quarter.
Ken Fisher began building the BBIO position before our 13F history starts, so an exact average buy price cannot be estimated without understating it. All figures come from SEC 13F filings for Q1 2026, the latest disclosed quarter.
13F filings disclose quarter-end holdings, not trade dates or execution prices. These estimates use each covered quarter's average market price; the add average excludes the opening position and quarters without price data. All figures come from SEC 13F filings for Q1 2026, the latest disclosed quarter.
